| Biomarker ID | 1596 |
| PMID | 26254378 |
| Year | 2015 |
| Biomarker | %fPSA |
| Biomarker Basis | Concentration Based (μg/L) |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Downregulated in PCa [BPH: 16.7 (1.8-45.4); PCa:11.7 (4.1-31.7)] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Prostate Cancer Vs Benign prostatic hyperplasia |
| Type of Biomarker | Diagnostic |
| Cohort | 150 patients with Benign Prostatic Hyperplasia and 113 with Prostate cancer were selected for the study |
| Senstivity | Cut off 15%: 61%; Cut off 20%: 30% |
| Specificity | Cut off 15%: 74%; Cut off 20%: 88% |
| AUC | 0.70062 |
| Accuracy | NA |
| Level Of Significance | p<0.0001 |
| Method Used | Chemiluminescence |
| Clinical | No |
| Remarks | %fPSA = (fPSA/tPSA x 100) |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |